BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cai Y, Feng R, Lu T, Chen X, Zhou X, Wang X. Novel insights into the m6A-RNA methyltransferase METTL3 in cancer. Biomark Res 2021;9:27. [PMID: 33879256 DOI: 10.1186/s40364-021-00278-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Dou X, Wang Z, Lu W, Miao L, Zhao Y. METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a m6A-YTHDF1 dependent way. BMC Pulm Med 2022;22:324. [PMID: 36008805 DOI: 10.1186/s12890-022-02119-3] [Reference Citation Analysis]
2 Ruan P, Wang S, Yang C, Huang X, Sun P, Tan A. m6A mRNA methylation regulates the ERK/NF-κB/AKT signaling pathway through the PAPPA/IGFBP4 axis to promote proliferation and tumor formation in endometrial cancer. Cell Biol Toxicol 2022. [PMID: 35971034 DOI: 10.1007/s10565-022-09751-z] [Reference Citation Analysis]
3 Zhou Y, Guo S, Li Y, Chen F, Wu Y, Xiao Y, An J. METTL3 Is Associated With the Malignancy of Esophageal Squamous Cell Carcinoma and Serves as a Potential Immunotherapy Biomarker. Front Oncol 2022;12:824190. [PMID: 35574315 DOI: 10.3389/fonc.2022.824190] [Reference Citation Analysis]
4 Wang N, Huo X, Zhang B, Chen X, Zhao S, Shi X, Xu H, Wei X. METTL3-Mediated ADAMTS9 Suppression Facilitates Angiogenesis and Carcinogenesis in Gastric Cancer. Front Oncol 2022;12:861807. [PMID: 35574388 DOI: 10.3389/fonc.2022.861807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Zhu Y, Peng X, Zhou Q, Tan L, Zhang C, Lin S, Long M. METTL3-mediated m6A modification of STEAP2 mRNA inhibits papillary thyroid cancer progress by blocking the Hedgehog signaling pathway and epithelial-to-mesenchymal transition. Cell Death Dis 2022;13:358. [PMID: 35436987 DOI: 10.1038/s41419-022-04817-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
6 Chen X, Zhou X, Wang X. m6A binding protein YTHDF2 in cancer. Exp Hematol Oncol 2022;11:21. [PMID: 35382893 DOI: 10.1186/s40164-022-00269-y] [Reference Citation Analysis]
7 Xu P, Ge R. Roles and drug development of METTL3 (methyltransferase-like 3) in anti-tumor therapy. European Journal of Medicinal Chemistry 2022;230:114118. [DOI: 10.1016/j.ejmech.2022.114118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liang X, Zhang Z, Wang L, Zhang S, Ren L, Li S, Xu J, Lv S. Mechanism of methyltransferase like 3 in epithelial-mesenchymal transition process, invasion, and metastasis in esophageal cancer. Bioengineered 2021;12:10023-36. [PMID: 34666602 DOI: 10.1080/21655979.2021.1994721] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
9 Sabnis RW. Novel METTL3 Modulators for Treating Acute Myeloid Leukemia (AML). ACS Med Chem Lett 2021;12:1061-2. [PMID: 34267869 DOI: 10.1021/acsmedchemlett.1c00280] [Reference Citation Analysis]
10 Takeda Y, Chijimatsu R, Vecchione A, Arai T, Kitagawa T, Ofusa K, Yabumoto M, Hirotsu T, Eguchi H, Doki Y, Ishii H. Impact of One-Carbon Metabolism-Driving Epitranscriptome as a Therapeutic Target for Gastrointestinal Cancer. Int J Mol Sci 2021;22:7278. [PMID: 34298902 DOI: 10.3390/ijms22147278] [Cited by in F6Publishing: 1] [Reference Citation Analysis]